Copyright Notice
Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Bookshelf ID: NBK592184PMID: 37247363
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 1448169-71-8
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the clinical use of futibatinib during breastfeeding. Because futibatinib is 95% bound to plasma proteins, the amount in milk is likely to be low. The manufacturer recommends that breastfeeding be discontinued during futibatinib therapy and for 1 week after the last dose.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Futibatinib
CAS Registry Number
1448169-71-8
Drug Class
Breast Feeding
Milk, Human
Enzyme Inhibitors
Protein Kinase Inhibitors
Signal Transduction Inhibitors
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.[Cancer Res. 2020]Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.Sootome H, Fujita H, Ito K, Ochiiwa H, Fujioka Y, Ito K, Miura A, Sagara T, Ito S, Ohsawa H, et al. Cancer Res. 2020 Nov 15; 80(22):4986-4997. Epub 2020 Sep 24.
- Review Ibrutinib.[Drugs and Lactation Database (...]Review Ibrutinib.. Drugs and Lactation Database (LactMed®). 2006
- Review Sotorasib.[Drugs and Lactation Database (...]Review Sotorasib.. Drugs and Lactation Database (LactMed®). 2006
- Review Leniolisib.[Drugs and Lactation Database (...]Review Leniolisib.. Drugs and Lactation Database (LactMed®). 2006
- Review Infigratinib.[Drugs and Lactation Database (...]Review Infigratinib.. Drugs and Lactation Database (LactMed®). 2006
- Futibatinib - Drugs and Lactation Database (LactMed®)Futibatinib - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...